The traditional arteriovenous endovascular fistulas for hemodialysis use autologous vascular anastomoses, such as cephalic vein-radial artery endovascular fistula and cephaloscopic brachial artery endovascular fistula, etc. Autologous arteriovenous endovascular fistulas should be the first choice for hemodialysis access in uremic patients, and this has become an expert consensus in the new treatment guidelines. For these patients, there are only two options: long-term placement of a deep vein or creation of an arteriovenous endovascular fistula using an artificial vessel. Compared to long-term placement of a deep vein, an arteriovenous endovascular fistula has obvious advantages: high long-term patency rate, less susceptibility to infection, and ease of living. The length and diameter of the artificial vessel can be freely chosen, so the artificial arteriovenous fistula can be established in many parts of the body, such as brachial artery-cephalic vein artificial vascular fistula, brachial artery-median elbow vein artificial vascular fistula, axillary artery-axillary vein artificial vascular fistula, brachial artery-axillary vein artificial vascular fistula, femoral artery-saphenous vein artificial vascular fistula, femoral artery-femoral vein artificial vascular fistula. The use of artificial vessels has become more and more widespread and has become a new dialysis access solution for uremic patients with poor autologous vascular conditions. In recent years, the author has used artificial vessels to surgically create arteriovenous endovascular fistulas for patients with poor autologous vascular conditions, all with good results.